KZA 0.00% 8.0¢ kazia therapeutics limited

Paxalisib it broadly recognised as remarkable Increasing...

  1. 2,795 Posts.
    lightbulb Created with Sketch. 1723


    Paxalisib it broadly recognised as remarkable Increasing efficacy by +60% on the current standard of care... in GBM the primary condition of focus

    Kazia identified a shelved molecule at the storied cancer drug development company, Genentech.

    In fact, Genentech has been so successful at therapeutic development, when Roche Holdings took them over, it chose to leave it completely intact so as not to destroy Genentech’s culture of success.

    Kazia felt there was a lot to like about the drug, named GDC-0084 at the time, and we concurred.

    Specifically:

    The science behind paxalisib was outstanding,
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.